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Maximal STAT5-induced proliferation and self-renewal 























The level of transcription factor activity critically regulates cell fate decisions such 
as hematopoietic stem cell self-renewal and differentiation. We have introduced 
STAT5A transcriptional activity into human hematopoietic stem/progenitor cells in a 
dose-dependent manner by overexpression of a tamoxifen-inducible STAT5A(1*6)-
ER fusion protein. Induction of STAT5A activity in CD34+ cells resulted in impaired 
myelopoiesis and induction of erythropoiesis which was most pronounced at the 
highest STAT5A transactivation levels. In contrast, intermediate STAT5A activity 
levels resulted in the most pronounced proliferative advantage of CD34+ cells. This 
coincided with increased Cobblestone Area Forming Cell (CAFC) and Long-term 
Culture-Initiating Cell (LTC-IC) frequencies that were predominantly elevated at 
intermediate STAT5A activity levels, but not at high STAT5A activity. Self-renewal 
of progenitors was addressed by serial replating of CFUs, and only progenitors 
containing intermediate STAT5A activity levels contained self-renewal capacity. By 
extensive gene expression profiling we could identify gene expression patterns of 
STAT5 target genes that predominantly associated with a self-renewal and long-
term expansion phenotype versus those that identified a predominant 
differentiation phenotype. 
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Introduction 
 
STAT5 (Signal Transducer and Activator of Transcription 5) is widely expressed 
throughout the hematopoietic system, both in stem and progenitor cells as well as 
in committed erythroid, myeloid and lymphoid cells1-3. Indeed, it is not surprising 
that STAT5 can be activated by a wide variety of cytokines and growth factors3,4. 
These include those that act on the most immature human hematopoietic stem 
compartment such as Flt3-ligand (FL)5, Stem Cell Factor (SCF)6 and 
Thrombopoietin (TPO)7, as well as those that act on erythroid cells (Erythropoietin, 
EPO)8, lymphoid cells (Interleukin-7, IL-7; IL-2)9 or myeloid cells (IL-3; IL-5; 
Granulocyte/Macrophage-Colony Stimulating Factor, GM-CSF; Colony Stimulating 
Factors-1, CSF-1)3. Loss-of-function and gain-of-function experiments have 
revealed critical roles for STAT5 in several of these cell types. STAT5ABΔN/ΔN mice, 
which express an N-terminally truncated form of STAT5, have been used to assess 
stem cell function in the absence of wt STAT5 signaling. These mice were 
characterized by normal HSC numbers and stem cells isolated from the bone 
marrow or fetal liver were capable of engrafting irradiated recipients10. Yet, 
competitive repopulating capacity of STAT5ABΔN/ΔN HSCs was severely impaired10-
15. The underlying mechanisms are not fully elucidated yet, but it has been 
observed that the responsiveness of STAT5ABΔN/ΔN HSCs to early-acting cytokines 
such as IL-3 and SCF was reduced, while the sensitivity to 5-fluoroacil was 
enhanced11. More recently, mice completely devoid of STAT5 expression were 
developed as well, and data have indicated that STAT5 is required for HSC, 
lymphocyte, and erythrocyte development16-18. We have observed that 
downmodulation of STAT5 expression impairs long-term self-renewal and 
maintenance of human stem and progenitor cells19. Reversely, it has been shown 
that introduction of activating mutants of STAT5 in hematopoietic stem and 
progenitor cells enhances long-term self-renewal20,21. Within the erythroid 
compartment, STAT5 fulfils an important anti-apoptotic role by upregulating Bcl-
Xl16,22-24, although a more direct role in initiating erythroid commitment might exist 
as well21,25,26. Although in the STAT5-/- mice myelopoiesis appears to be relatively 
unaffected18, it is likely that in myeloid cells many of the signals initiated by e.g. IL-3 
and GM-CSF are, at least in part, mediated by STAT527,28. STAT5 is also involved 
in eosinophil differentiation of human CB CD34+ cells in response to IL-529. Also, 
lymphoid development is severely impaired in STAT5-/- mice30. These studies have 
highlighted that STAT5 signaling is involved at various stages throughout 
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hematopoietic development. Yet, little is known about the kinetics of cytokine-
induced STAT5 signaling, or in which fashion STAT5 responds to lineage-restricted 
cytokine exposure. Also, it is currently unclear whether similar levels of STAT5 are 
required for the various functions that this transcription factor fulfils within the 
hematopoietic system. 
Besides a role in normal hematopoiesis, elevated STAT signaling has been 
associated with leukemic transformation as well. Overexpression of a STAT5A 
S710F mutant (cSF5F) in murine bone marrow resulted in the development of 
multilineage leukemias upon transplantation into lethally irradiated wild-type or non-
irradiated Rag2(-/-) mice31. The underlying mechanisms might involve STAT5 
tetramer formation31 but cytoplasmic STAT5 functions have recently been 
described as well, whereby STAT5 forms a complex with PI-3K and Gab2, resulting 
in activation of the Akt/PKB pathway32. Other mechanisms by which STAT5 can 
contribute to the transformation process are the induction of genomic instability and 
DNA damage33, e.g. by upregulation of reactive oxygen species (ROS)34. 
Constitutive activation of STAT5 has been observed in the vast majority of Acute 
Myeloid Leukemia (AML) cases35-37. This may be attributed to the activating 
mutations in upstream kinases such as FLT3, c-KIT or JAK21, or alternatively be 
due to autocrine growth factor production35. In primary AML CD34+ cells, we have 
recently been able to demonstrate that downmodulation of STAT5 expression by 
lentiviral RNAi impairs long-term expansion of leukemic stem/progenitor cells19. In 
murine cells, constitutive activation of STAT5 is sufficient to induce leukemia-like 
disease31,38. Elevated STAT5 signaling is also involved in the pathogenesis of other 
haematological malignancies, including Chronic Myeloid Leukemia (CML) induced 
by BCR-ABL39-44 or Polycythemia Vera (PV) induced by activated JAK2 V617F45-47. 
Little information is currently available regarding mechanisms that are involved in 
STAT5-induced transformation. Recent reports highlighted the importance of 
transcription factor dosage that is associated with malignant transformation. 
Examples include PU.1, which is highly leukemic in murine models when 
expressed at 20% of normal endogenous levels, while complete loss or 
heterozygous dosage is not leukemic48. Furthermore, low levels of C/EBPα are 
associated with leukemic transformation of myeloid lineages, while increased 
expression results in B-ALL49. Based on these findings we analyzed the effects of 
STAT5 in a dose-dependent manner on hematopoietic stem cell self-renewal and 
differentiation. We observed that at a low to intermediate STAT5 activity maximal 
effects on self-renewal of stem and progenitor cells were obtained in conjunction 
with long-term expansion. High STAT5 activity levels resulted in a predominant 
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erythroid commitment with impaired myeloid development. Gene expression 
profiling over a range of STAT5 activities in human CB CD34+ cells revealed 
subsets of genes that were associated with the ‘self-renewal and long-term 
expansion’ phenotype. This subset contained (besides known growth-promoting 
genes such as PIM1 and CYCLIN D2) a large set of genes encoding membrane 
and membrane-associated proteins. 
 
 
Materials and Methods 
Cell culture and retroviral transductions 
 
CD34+ cells were derived from neonatal cord blood from healthy full-term 
pregnancies from the Obstetrics departments of the Martini Hospital and University 
Medical Center in Groningen, The Netherlands, after informed consent. The 
protocol was approved by the Medical Ethical Committee of the UMCG. For all 
retroviral transduction experiments, the murine stem cell virus (MSCV) retroviral 
expression vector was used which contained an encephalo-myelocarditis virus 
(EMCV) derived internal ribosomal entry site (IRES2) in front of the truncated 
Neural Growth factor Receptor (NGF-R) (MiNR1 vector). The STAT5A(1*6) 
retroviral vector was described previously21,50. STAT5A(1*6)-ER was constructed 
by fusing the STAT5(1*6) cDNA, from which the stop codon was removed by PCR 
mediated mutagenesis, to the cDNA of the ligand binding domain of the murine 
estrogen receptor in pBlueScript (kindly provided by Hergen Spits, Department of 
Cell Biology and Histology, University of Amsterdam, The Netherlands). The 
resulting cDNA was cloned into the EcoRI site of pMSCV-iNGFR. pMSCV-
STAT5A(S710F) was made by replacing the BamHI / NsiI fragment from pMSCV-
STAT5(1*6) with the same fragment from pMSCV-STAT5A(wt). Cloning of 
STAT5A(S710F)-ER and STAT5A(wt)-ER was done in a similar way as pMSCV-
STAT5(1*6) using cDNA from the corresponding pMSCV vectors. Details of the 
cloning and primer sequences are available upon request. pMSCV-STAT5B-ER 
was made by  cloning the STAT5B-ER cDNA (kindly provided by Hergen Spits, 
Department of Cell Biology and Histology, University of Amsterdam, The 
Netherlands)  from pLZRS into the EcoRI site of  the pMSCV-iNGFR vector. Stable 
PG13 high titer retroviral producer cell lines were generated and CB CD34+ cells 
were transduced in three consecutive rounds as described previously21,50. 
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Stromal Coculture assays, Colony Forming Cell (CFC), Cobblestone Area 
Forming Cell (CAFC), LTC-IC and 2nd CFC assays 
 
MS5 cocultures were performed as described previously. Briefly, MS5 stromal cells 
were preplated on T25 flasks in αMEM supplemented with 10% Horse serum 
(Sigma, Zwijndrecht, The Netherlands), penicillin and streptomycin and 200 mM 
Glutamine and cells were grown to full confluency. 3x104 transduced CB CD34+ 
cells were plated on MS5 in LTC medium (αMEM supplemented with heat-
inactivated 12.5% FCS, heat-inactivated 12.5% Horse serum (Sigma, Zwijndrecht, 
The Netherlands), penicillin and streptomycin, 200 mM Glutamine, 57.2 µM β-
mercaptoethanol (Sigma) and 1 µM hydrocortisone (Sigma)). Half of the cultures 
was removed weekly and was replaced with fresh LTC medium. Harvested cells 
were counted and analyzed by FACS and progenitor content (CFCs) as indicated 
in the text. CFC assays were performed as described previously. Briefly, CFC 
assays were performed in MethoCult H4230 (StemCell Technologies, Grenoble, 
France) supplemented with 20 ng/ml Interleukin-3 (IL3), 20 ng/ml IL-6, 20 ng/ml G-
CSF, 20 ng/ml c-Kit ligand (KL) and 6 U/ml EPO. 103-104 cells were plated in 
methylcellulose per plate in duplicate. For 2nd CFC assays, cells were harvested 
from methylcellulose after two weeks, washed three times with PBS, and replated 
into new methylcellulose for another two weeks after which 2nd CFCs were 
enumerated. CAFC and LTC-IC assays were performed by plating transduced CB 
CD34+ cells in limiting dilutions in the range of 6-1458 cells per well on MS5 
stromal cells in 96-well plates in LTC medium. Cultures were weekly fed with new 
medium and after 5 weeks, methylcellulose was added to the wells. Two weeks 
later, wells containing CFCs were scored as positive. CAFC assays were 
performed as LTC-IC assays, but now CAFCs were counted at day 10 and at week 
5 by microscopic evaluation of cocultures and phase dark colonies underneath the 




Total RNA was isolated using the RNeasy kit from Qiagen (Venlo, The 
Netherlands) according to the manufacturer’s recommendations. For real-time RT-
PCR, cDNA was prepared by reverse transcribing the total RNA of 0.15 x 106 
sorted cells using M-MuLV reverse transcriptase (Fermentas GmbH, St. Leon-
Roth, Germany) according to the manufacturer’s instructions. cDNA was diluted 20 
fold and 3 µl was then real-time amplified using iQ SYBR Green supermix (Bio-
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Rad, Veenendaal, the Netherlands) in a MyIQ thermocycler (Bio-Rad) and 
quantified using MyIQ software (Bio-Rad). HPRT, RPL27 and RPL30 expression 
levels51 were used to normalize between samples and to calculate relative 
expression levels. Primers and conditions are indicated in Supplementary Table 1.  
Genome-wide expression analysis was performed on Illumina (Illumina, Inc., San 
Diego, CA) BeadChip Arrays Sentrix Human-6 (46k probesets). Typically, 0.5-1 µg 
of mRNA combined from three independent transduction experiments was used in 
labeling reactions and hybridization with the arrays according to the manufacturer’s 
instructions. Data was analyzed using the BeadStudio v3 Gene Expression Module 
(Illumina, Inc.) and Genespring (Agilent, Amstelveen, The Netherlands). 
 
Flow cytometry analysis 
 
All antibodies were obtained from Beckton Dickinson (Alphen a/d Rijn, The 
Netherlands). Cells were incubated with antibodies at 4°C for 30 min.  All 
fluorescence activated cell sorter (FACS) analyses were performed on a 
FACSCalibur (Becton Dickinson) and data was analyzed using WinList 3D 
(Topsham, USA). Cells were sorted on a MoFLo (DakoCytomation, Carpinteria, 
CA, USA). 
 
Electrophoretic Mobility Shift Assays (EMSAs) 
 
Nuclear extracts of retrovirally transduced KG1a cells were made according to the 
mini scale procedure. EMSA analysis was performed by incubating 5 µg of nuclear 
extract with 5’-IRDye 700 labeled double stranded oligonucleotides for 30 minutes 
at room temperature. Binding reactions were run on non-denaturing 4 % 
Acrylamide gels in 1 x TBE and the gels were scanned using an Odyssey infrared 
scanner (Li-Cor Biosciences, Lincoln, NE, USA). To check for specificity of the 
reactions, 50 fold molar excess of unlabeled oligonucleotide (either self or non-self) 
was added to the binding reactions. For supershift analysis, 1 µl of STAT5-specific 
antibody (C17, Santa Cruz Biotech, Santa Cruz, CA, USA) was added 
simultaneously with the probe. 
 
Immunoblotting, histochemistry and cytospins 
 
Nuclear extracts were obtained as described above.  Laemmli sample buffer was 
added to the samples, and samples were boiled for 5 min prior to separation on 
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12% SDS-acrylamide gels. Proteins were transferred to PVDF membrane 
(Millipore, Etten Leur, The Netherlands) by semidry electroblotting. Membranes 
were blocked in Odyssey blocking buffer prior to incubation with antibodies. 
Binding of antibodies was detected by incubating with Alexa680 or IRDye800 
labeled secondary antibodies (Invitrogen, Breda, the Netherlands) and scanning of 
the membrane on an Odyssey infrared scanner (Li-Cor Biosciences, Lincoln, NE, 
USA). Antibodies against STAT5 (C17) were obtained from Santa Cruz (Santa 
Cruz Biotech, Santa Cruz, CA, USA) and antibodies against tyrosine 
phosphorylated STAT5 (pY694, C11C5) were obtained from Cell Signaling 
Technologies (Leiden, The Netherlands) and were used in dilutions of 1:1000. 




For transactivation studies, 293T cells were transiently transfected in 12-well plates 
with the indicated constructs using Fugene6 (Roche, Basel, Switserland) according 
to the manufacturer’s instructions. Cells were transfected with a luciferase vector 
containing  3 STAT5-binding sites from the beta-casein promoter (3xGAS-luc), 
together with a pDM-LacZ vector as an internal control for transfection efficiency. 
24 hours after transfection, cells were stimulated for 24 hours with 0-500 nM 4-
hydroxy tamoxifen (Sigma) to induce STAT5 activation and cell extracts were made 
using Luciferase lysis buffer (Promega, Leiden, the Netherlands). Luciferase 
expression was measured according to the manufacturer’s protocol (Promega, 
Leiden, the Netherlands). β-galactosidase expression was measured to correct for 





Dose-dependent induction of STAT5A activity in human CD34+ cells 
 
In order to generate a system in which STAT5 transactivity levels could be 
introduced into primary human CD34+ cells in a dose dependent manner, we 
constructed a fusion protein of the STAT5A(1*6) mutant with the modified ligand- 
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Figure 1. Dose-dependent induction of STAT5 activity using 4-OHT-inducible STAT5A(1*6)-ER 
fusion proteins. A, Schematic representation of the retroviral vectors used in this study. B, Western 
blot of nuclear extracts of KG1a cells transduced with MiNR1 control or STAT5A(1*6)-ER vectors. Cells 
were stimulated with 4-OHT in concentrations from 0-500 nM for 24 hrs as indicated and lysates were 
probed using antibodies against STAT5 and tyrosine 694 phosphorylated STAT5. C, Electrophoretic 
Mobility Shift Assay (EMSA) using nuclear extracts of MinR1 and STAT5A(1*6)-ER-transduced KG1a 
cells using a STAT5-specific probe from the beta-casein promoter.. Cells were stimulated with 500 nM 
4-OHT for 24 hrs or left unstimulated as indicated and nuclear extracts were prepared. Supershift 
experiments were performed using antibodies against STAT5. D, EMSA experiment as in C, but now 
cells were stimulated in a dose-dependent manner with 4-OHT as indicated. E, 293T cells were 
transiently transfected with MiNR1 or STAT5A(1*6)-ER vectors together with a luciferase reporter 
containing three STAT5 binding sites in the promoter. Cells were stimulated with 4-OHT in a dose-
dependent manner as indicated for 24 hrs and cell lysates were prepared and analyzed for luciferase 
activity. F, CB CD34+ cells were transduced with STAT5A(1*6)-ER, stimulated with 4-OHT in a dose-
dependent manner as indicated for 24 hrs and RNA was isolated. Q-PCR analysis was performed using 
primers against SOCS2. Q-PCR data were compared to results obtained from gene expression profiling 
using Illumina BeadChip Arrays. G, CB CD34+ cells were stimulated with a cocktail of cytokines (c-KIT 
ligand, FLT3-ligand, and Thrombopoietin (KFT)) in a dose-dependent manner as indicated. Total cell 
lysates were prepared and Western blotting was performed using antibodies against STAT5 and 
tyrosine 694 phosphorylated STAT5. H, CB CD34+ cells were transduced with wt STAT5A-ER and 
stimulated with 10 ng/ml IL3, 400 nM 4-OHT, or both. Total cell lysates were prepared and Western 
blotting was performed using antibodies against STAT5 and tyrosine 694 phosphorylated STAT5. I, CB 
CD34+ cells were stimulated with in creasing concentrations of KFT as in G, or transduced with 
STAT5A(1*6)-ER or wt STAT5A-ER after which cells were stimulated with 4-OHT as in B (for wt 
STAT5A-ER 0, 3.2, 16, 80, 400, and 2000 nM 4-OHT was used). RNA was isolated and Q-PCRs were 




binding domain (LBD) of the Estrogen Receptor that is responsive to 4-hydroxy 
tamoxifen. STAT5A(1*6)-ER was inserted into the retroviral MiNR1 vector 
(schematically depicted in Fig.1A). Dose-dependent STAT5A inducibility was first 
tested in 293T human kidney and KG1a cells and later in transduced CB-derived 
CD34+ cells. Western blotting of nuclear extracts of transduced KG1a cells 
revealed that STAT5 tyrosine 694 phosphorylation and nuclear translocation could 
be induced in a dose-dependent manner upon treating cells with increasing 
concentrations of 4-OHT (Fig.1B). Specific STAT5A DNA-binding was determined 
by Electrophoretic Mobility Shift Assays (EMSA) and supershift experiments 
(Fig.1C), which could also be induced in a dose-dependent manner upon 
increasing concentrations of 4-OHT (Fig.1D). STAT5A transactivation was 
determined by transient transfections of 293T cells with the STAT5A(1*6)-ER 
fusion together with a 3x-GAS-luciferase reporter, and these studies also revealed 
a dose-dependent induction of STAT5A transactivation upon treatment with 
increasing concentrations of 4-OHT (Fig.1E). To study the effects of STAT5 
transactivation on the expression of endogenous target genes, CB CD34+ cells 
were retrovirally transduced with STAT5A(1*6)-ER and RNA was isolated from 
cells that were treated with increasing concentrations of 4-OHT for 24 hrs. Illumina 
microarray analysis as well as Q-PCR analysis revealed that STAT5 target genes 
were induced in a dose-dependent manner and an example for SOCS2 expression 
is shown in Fig.1F.  
Finally, we wished to determine how the induced STAT5A(1*6)-ER transactivity 
levels compare to normal endogenous STAT5 activity levels induced by cytokines 
as well as to wt STAT5A-ER activity levels. CB CD34+ cells were stimulated with 
the cytokines c-KIT-ligand, FLT3-ligand and Thrombopoietin (KFT) in increasing 
concentrations and STAT5 tyrosine 694 phosphorylation was determined by 
Western blotting. As shown in Fig.1B and Fig.1G, 4-OHT-induced STAT5A(1*6) 
tyrosine phosphorylation was within a similar range and never exceeded 
endogenous STAT5 phosphorylation levels induced by cytokines. Furthermore, 
endogenous IL-3-induced STAT5 signaling was compared to wt STAT5A-ER 
signaling in CB CD34+ cells. IL-3-induced STAT5A tyrosine phosphorylation was 
comparable to wt STAT5A-ER tyrosine phosphorylation induced by 4-OHT 
(Fig.1H).  Moreover, similar observations were done in Q-PCR analyses for STAT5 
target genes and an example is shown in Fig.1I in which cytokine-induced CISH 
expression was within a similar range compared to STAT5A(1*6)-ER and wt 
STAT5A-ER-induced CISH expression, whereby somewhat higher 4-OHT 
concentrations were required to activate the wt STAT5A-ER molecules.  
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Figure 2. Maximal proliferative advantage of CB CD34+ cells at intermediate STAT5A activity 
levels while differentiation is most affected at high STAT5A transactivation levels. A, CB CD34+ 
cells were transduced with MiNR1 control or STAT5A(1*6)-ER vectors and cocultures were initiated on 
MS5 bone marrow stromal cells in the presence of 4-OHT concentrations ranging from 0-500 nM as 
indicated. Cultures were weekly demidepopulated and cumulative cell counts of a representative 
experiment (out of three) are indicated. B, Experiment as in A, but now cells were transduced with 
MiNR1 control or STAT5A(S710F)-ER vectors. C, Experiment as in A, but now cells were transduced 
with MiNR1 control or wt STAT5A-ER vectors and cocultures were initiated on MS5 bone marrow 
stromal cells in the presence of 4-OHT concentrations ranging from 0-2000 nM. D, experiment as in A, 
but now cells that were harvested by weekly demidepopulation were analyzed by FACS for expression 
of myeloid (CD14, CD15) and erythroid (GPA) antigens. Data from a representative week 2 experiment 
is shown. E, Experiment as in A, but now cells harvested at week 2 were analyzed by cytospin and 
May-Grunwald-Giemsa staining. F and G, Experiments as in B and C, but now cells that were harvested 
by weekly demidepopulation were analyzed by FACS for expression of myeloid (CD14, CD15) and 
erythroid (GPA) antigens. Data from representative week 2 experiments are shown.  
 
 
Proliferative advantage of CD34+ cells is most pronounced at intermediate 
STAT5A activity levels 
 
CB CD34+ cells were transduced with MiNR1 empty vectors or STAT5A(1*6)-ER 
vectors, and cocultures on MS5 bone marrow stroma were initiated. 4-OHT was 
added to the cocultures in concentrations from 0-500 nM. Cultures were weekly 
demidepopulated and expansion of suspension cells was monitored. Control 
MiNR1 cultures expanded about 15 to 20-fold over a period of three weeks, which 
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was not affected by addition of 4-OHT to the cultures (Fig.2A). Activation of 
STAT5A resulted in a proliferative advantage as we have observed before21, but 
surprisingly the maximum fold expansion of over 80-fold within three weeks was 
not reached in the groups with the highest STAT5 activity levels (Fig.2A). Rather, 
transduced CD34+ cells treated with 20nM 4-OHT resulting in intermediate STAT5 
activity levels displayed the maximal proliferative advantage (Fig.2A). In order to 
determine whether the effects on proliferation were specific for the STAT5A(1*6)-
ER mutant, we repeated  the co-culture experiments with STAT5A S710F-ER and 
wild-type STAT5A-ER (Fig.2B and B) as well as with STAT5B-ER (data not shown) 
and basically similar results were observed, albeit with somewhat different kinetics. 
STAT5A(S710F)-ER reached maximal long-term expansion at 20 nM (Fig.2B) 
whereby the maximal number of CAFCs was observed. While at 500 nM a strong 
expansion was observed at week 1, this expansion was transient and all cells 
differentiated towards an erythroid fate and no long-term cultures could be 
maintained after three weeks of MS5 coculture. Maximal wt STAT5A-ER induced 
proliferation was reached at 400 nM 4-OHT, which was not further increased upon 
further activation of STAT5 (Fig.2B). 
 
Impaired myelopoiesis and induction of erythropoiesis at high STAT5A 
transactivation levels 
 
Hematopoietic differentiation was monitored in suspension cells from MS5 
cocultures by FACS and morphological analysis of cytospins by MGG staining. As 
observed previously21, STAT5A activation impairs myelopoiesis, as demonstrated 
by a reduction in cells that express monocytic and granulocytic antigens CD14 and 
CD15 (Fig.2D), while erythroid differentiation was induced as demonstrated by an 
increase in cells expressing Glycophorin A (Fig.2C), CD36 and CD71bright (data not 
shown). Analysis of cytospins of suspension cells at week two yielded similar 
results, with an impairment of myelopoiesis and an induction of erythropoiesis upon 
STAT5 activation (Fig.2E). Importantly, maximum inhibition of myelopoiesis was 
observed at the highest STAT5 activity levels (Fig.2D). These data contrast our 
observations related to the proliferative capacity of cells which were maximal at 
intermediate STAT5 activity levels. Maximal erythroid differentiation and impaired 
myeloid differentiation were also achieved at the highest STAT5A S710F-ER and 
wt STAT5A-ER (Fig.2F and G) and STAT5B-ER (data not shown) activity levels. 
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Figure 3. Self-renewal of progenitors at 
intermediate STAT5A activity levels. CB CD34+ 
cells were transduced with MiNR1 control or 
STAT5A(1*6)-ER vectors, cells were plated into 
methylcellulose in the presence of 4-OHT in 
concentrations as indicated. Progenitor numbers 
were scored two weeks later. After scoring, cells 
were harvested, washed with PBS and were 
replated into new methylcellulose to initiate 2nd 
CFC assays, which were scored two weeks after 













Self-renewal of progenitors at intermediate STAT5A activity levels 
 
To address the self-renewal capacity of hematopoietic progenitors, CB CD34+ cells 
were transduced with MiNR1 controls vectors or STAT5A(1*6)-ER, and 103 cells 
were plated in methylcellulose in duplicate in the absence or presence of 
increasing concentrations of 4-OHT. As depicted in Fig.3A, increasing STAT5 
activity levels resulted in a dose-dependent reduction in CFCs. No apoptotic cells 
were observed, suggesting that reduced proliferation or differentiation beyond the 
progenitor stage was involved rather than programmed cell death (data not shown). 
After two weeks, CFC colonies were harvested and replated into fresh 
methylcellulose. Only cells that were cultured with low concentrations of 4-OHT 
were capable of giving rise to 2nd CFCs (Fig.3A, right panel). Secondary colonies 
were exclusively of myeloid origin, while erythroid colonies lacked replating 
capacity. Thus, low to intermediate STAT5 activity levels could confer self-renewal 





Figure 4. CAFC and LTC-IC frequencies are increased at intermediate, but not high, STAT5A 
activity levels. A, CB CD34+ cells were transduced with MiNR1 control or STAT5A(1*6)-ER vectors 
and cocultures were initiated on MS5 bone marrow stromal cells in limiting dilution on 96-well plates in 
the presence of 4-OHT concentrations ranging from 0-500 nM as indicated. Early cobblestone areas 
were enumerated at week 2 (n=3). B, Experiment as in A, and representative images of cocultures at 
week 2 are shown. C, Stem cell frequencies were determined in LTC-IC assays in limiting dilution in 96-
well plates on MS5 stroma by plating MiNR1 or STAT5A(1*6)-ER-transduced cells in concentrations of 
6-1458 cells per well. Cultures were weekly fed with new medium, and at week 5 methylcellulose was 
added and LTC-IC frequencies were determined two weeks later. Data from two representative 
experiments is shown (in C and D). Panels on the left display all LTC-IC data over a range of plated cell 
densities without 4-OHT or in the presence of 500 nM 4-OHT. The panel on the right displays LTC-IC 
frequencies over a range of 4-OHT concentrations as indicated. E, Similar experiments as in C and D, 
but now stem cell frequencies were determined in LTC-IC assays in limiting dilution in 96-well plates on 
MS5 stroma by plating wt STAT5A-ER-transduced cells. 
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CAFC and LTC-IC frequencies are increased at intermediate, but not at high 
STAT5A activity levels 
 
To determine the effects of dose-dependent STAT5 signaling on the human 
hematopoietic stem cell population, CAFC and LTC-IC assays were performed. 
Previous studies have shown that induction of STAT5A activity facilitates the 
interaction of human CD34+ cells with bone marrow stroma. These data indicated 
that activation of STAT5 induces HSCs into a ‘hyperactive’ state with the capacity 
to form CAFCs underneath bone marrow stromal cells that retain the capacity for 
long-term ex-vivo self-renewal21. First we determined the formation of CAFCs at 
week 2 in sorted transduced cells that were plated in limiting dilution in 96-well 
plates on MS5 bone marrow stromal cells. Control MiNR1 cells normally do not 
form CAFCs until week 5 in these cocultures and indeed no CAFCs were observed 
in MiNR1 control cells at week 2 (Fig.4A). In contrast, upon induction of STAT5A 
activity early CAFCs appeared within 1 week after plating which persisted to grow 
for over 5 weeks (Fig.4A and B). Importantly, the highest CAFC frequencies were 
observed at intermediate STAT5A activity levels (20 nM 4-OHT) and CAFC 
frequencies were significantly lower at high STAT5A activity levels (500 nM 4-
OHT). Representative photographs of MS5 cocultures at week 2 are shown in 
Fig.4B. LTC-IC frequencies were determined in limiting dilution in 96-well plates, 
and in line with our CAFC data at week 2, LTC-IC frequencies were significantly 
enhanced upon induction of STAT5A activity, which were maximal at intermediate, 
but not the highest, STAT5A activity levels (2 representative experiments are 
shown in Fig.4C). Similar results were obtained in experiments in which CB CD34+ 
cells were transduced with wt STAT5A-ER vectors whereby maximal LTC-IC 
frequencies were observed at intermediate STAT5 activity levels (Fig.4E). 
 
Genome-wide changes in gene expression induced by dose-dependent 
STAT5 signaling 
 
In order to correlate global changes in gene expression with levels of STAT5A 
transactivity, Illumina BeadChip array analysis were performed using 
STAT5A(1*6)-ER-transduced CD34+ cells that were stimulated with increasing 
concentrations of 4-OHT (0-500 nM) for 24 hrs. mRNA was isolated from 
transduced and MoFlo-sorted cells which was used to hybridize human Illumina 
BeadChip Arrays that contain 46k probe sets. STAT5 expression levels, as well as 
the number and location of retroviral integration sites, were identical in all groups  
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as one batch of CD34+ cells was divided into six groups after transduction and 
MoFlo sorting that then received a certain dose of 4-OHT. Data was first analyzed 
by identifying significant changes in gene expression that were induced at 
intermediate STAT5A activity levels (20 nM versus 0 nM 4-OHT; fold change>2; 
p<0.05). Thus, 437 changes in gene expression were identified, which are 
presented in Fig.5 and Supplemental Table 2. Of the 437 changes, 220 genes 
were upregulated and 217 were downregulated (Fig.5, Supplemental Table 2).  A 
number of the changes in gene expression were verified by independent Q-PCR 
analysis and we observed that the Illumina BeadChip Array analyses were in good 
agreement with data obtained by Q-PCR (26 out of 29 changes identified by 
Illumina BeadChip Arrays were confirmed by Q-PCR, Supplemental Fig.1). To 
determine whether the identified target genes were indeed potential STAT5 target 
genes or whether they were specific for the STAT5A(1*6)-ER mutant we also 
performed gene expression studies on CB CD34+ cells transduced with wt 
STAT5A-ER vectors that were stimulated with 0 or 500 nM 4-OHT. Fold changes 
are included in Supplemental Table 2 and Supplemental Figure 1 and we observed 
that the expression of the vast majority of identified genes was affected by both the 
STAT5A(1*6)-ER and wt STAT5A-ER in a similar manner, although the fold 
changes were typically somewhat lower in the wt STAT5A-ER transduced cells. 
As we observed different phenotypes at 20 nM (predominant long-term growth and 
self-renewal) and 500 nM (predominant erythroid differentiation, schematically 
represented in Fig.6), we analyzed our datasets in order to determine which 
differences in gene expression between these groups might exist. We noted that 
within the upregulated genes, two subgroups could be identified. In one subgroup 
maximal gene expression induced by STAT5 was reached at 20 nM 4-OHT 
(‘[STAT5]int’ group, defined by 20 nM > 0 nM (>2-fold) and 500 nM = 20 nM (+/- 
20%). This group contained 138 changes (Supplemental Table 3). A second 
subgroup contained genes that responded in a more linear fashion upon increasing 
STAT5 activity (‘linear up’ group, defined by 20 nM > 0 nM (>2-fold) and 500 nM > 
20 nM (>1.2 fold)). This group contained 60 changes (Supplemental Table 4). The 
‘[STAT5]int’ group contained genes such as PIM1, GATA2, Insulin Growth factor 
Binding Protein 4 (IGFBP4), IGFBP5, CISH, Calbindin 2 (CALB2), Interleukin 3 
Receptor alpha (IL3Ra), Integrin 2 (ITGA2) and MUC1. The oncogene MAF was 
also upregulated maximally at intermediate STAT5 activity levels. The ‘linear up’ 
group contained genes such as Suppressor of Cytokine Signaling 2 (SOCS2), and 
Regulator of G-protein Signaling 1 (RGS1), as well as various novel potential 
STAT5 target-genes including members of the CCL chemokine family (CCL2, -3, - 
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5, -22). Q-PCR analysis also revealed that Bcl2 and p21 are induced by STAT5 in 
a linear fashion (Fig.5). 217 genes were found to be downregulated by induction of 
STAT5A activity in CD34+ cells (20 nM < 0 nM 4-OHT (>2-fold)) and this group 
included CXCR4, Neutrophil Elastase (ELA2) and C/EBPα, genes that we 
previously identified as being downmodulated via STAT5A21,50 as well as various 
novel STAT5-regulated genes including Gap Junction protein Alpha 4 (GJA4) and 
Rho GTPase activating protein 21 (ARHGAP21)   (Fig.5, Supplemental Table 2).  
We annotated the groups of genes according to biological process, cellular 
component and molecular function. It was striking to observe that genes within the 
[STAT5]int group were strongly enriched for membrane (p=0.0152), integral to 
membrane (p=0.00548), and intrinsic to membrane (p=0.00563) categories (Table 
1, Figure 5). Genes within this group are listed and further annotated in 
Supplemental Table 3. These categories were absent from the ‘linear up’ group, 
which was most strongly enriched for genes belonging to the extracellular space 
(p=4.80E-05) category (Table 1, Fig.5). The downmodulated group was enriched 
for plasma membrane categories (p=0.000586), and also contained actin 






The balance between hematopoietic stem cell self-renewal and differentiation 
needs to be tightly controlled, as a shift towards differentiation might exhaust the 
stem cell pool while a shift towards self-renewal might mark the onset of leukemic 
transformation. A number of transcription factors have been proposed to be 
critically involved in governing stem cell fate and lineage commitment, and these 
include HOX transcription factors52, c-MYC53, NOTCH154, β-CATENIN55, C/EBPα56, 
PU.157 and STAT518,20,21. It is therefore no surprise that dysregulation of these 
transcription factors can contribute to the development of leukemias. Over the past 
few years it has become increasingly evident that the dose of transcription factor 
activity is highly critical in determining cellular fates, whereby low versus high levels 
of activity might associate with very different phenotypes. Here, we describe that 
maximal self-renewal and long-term expansion is induced in human 
stem/progenitor cells by relatively low STAT5 transcriptional  
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Figure 6. Proposed model for dose-
dependent STAT5 signaling in human 
CD34+ cells. Intermediate STAT5 activity 
levels induce maximal self-renewal and 
long-term proliferative advantage. High 
STAT5 activity levels predominantly 
associate with an induction of 
erythropoiesis and impaired myelopoiesis. 
Intermediate STAT5 levels are sufficient to 
induce maximal levels of growth promoting 
oncogenes such as PIM1 and MAF, or low 
levels of C/EBPα, as well as maximal 
levels of membrane-associated genes 
such as MUC1 that might mediate the 
enhanced interaction between human 
hematopoietic stem/progenitor cells with 
their bone marrow microenvironment. This 
pattern of gene expression will drive long-
term expansion and self-renewal. Upon further increases in STAT5 activity, only specific subsets of 
STAT5 target genes will be further enhanced, and these include p21CIP and members of the 
chemokine family. These will negatively affect cell cycle progression and expansion, resulting in a shift 
towards a differentiation phenotype along the erythroid lineage. 
 
activity levels, while high STAT5 activity levels predominantly result in erythroid 
commitment without long-term growth. 
Maybe the clearest example to date that illustrates transcription factor dosage is 
PU.1. This transcription factor fulfils a variety of functions within the hematopoietic 
system, including maintenance of the stem cell pool, the generation of myeloid and 
lymphoid progenitors, as well as monocytic differentiation57. While a 50% reduction 
in PU.1 expression did not result in severe phenotypes, a reduction to 20% of 
normal PU.1 levels was shown to be highly leukemogenic48. Complete deletion of 
the PU.1 locus did not induce leukemia, and these data convincingly indicate that 
the levels of PU.1 are highly important in determining the phenotype. Other 
examples include c-MYC, which is thought to be expressed at very low levels in 
resting HSCs, but its expression increases upon HSC activation and is high in 
proliferating progenitors53. Enforced overexpression of c-MYC in HSCs resulted in 
a quick loss of stem cells presumably due to the induction of differentiation. 
NOTCH1, when expressed at high levels in neural stem cells leads to growth 
arrest, while low levels of the active form promote proliferation58. In human CD34+ 
cells, overexpression of the active form of NOTCH1 has resulted in opposing 
phenotypes, ranging from the induction of apoptosis59 to stem cell expansion54 and 
it is well plausible that the dose of active NOTCH1 is critical in determining the 
phenotype. Activation of β-CATENIN by WNT3A was suggested to enhance stem 
cell self-renewal55, although a loss of hematopoietic stem cell repopulation and a 
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block in multilineage differentiation was reported by others60,61, which might well be 
explained by different dosages of β-CATENIN activity that were introduced. 
These examples illustrate that the level of transcription factor activity that is 
introduced within the hematopoietic stem/progenitor compartment strongly 
influences the decision whether to self-renew, proliferate or differentiate. In the 
present study we have used a model system in which the transcription factor 
activity of STAT5 could be tightly controlled by making use of 4-OHT-inducible 
chimeras of the modified Estrogen Receptor ligand binding domain fused to 
STAT5. Even though this 30 kDa domain is relatively large and we therefore 
cannot exclude the possibility that target gene expression might be altered by for 
instance changing STAT5 tetramer formation31, we have observed induction of the 
known previously described STAT5 target genes with our ER fusion molecules. 
Thus, this approach allowed us to perform gene-dosage experiments in transduced 
human CD34+ stem/progenitor cells in relation to self-renewal, long-term expansion 
and differentiation. Our studies revealed that low to intermediate STAT5 activity, 
but not high levels of STAT5 activity, are required to induce optimal self-renewal 
and long-term expansion on stroma. This intermediate STAT5 activity was 
associated with the formation of cobblestone area (CA) formation underneath the 
bone marrow stroma within a few days after plating, and these CAs contain self-
renewing cells as demonstrated by their serial replating capacity21,25,62. In fact, this 
interaction with bone marrow stroma was required for self-renewal as no long-term 
cultures could be established in cytokine-driven liquid cultures using cells 
transduced with either activated STAT5 or FLT3-ITD21,63. Genome-wide gene 
expression analysis revealed that at intermediate STAT5 activity levels this group 
was significantly enriched for genes encoding for membrane proteins. These 
include membrane proteins that have been associated with adhesion, such as 
Protocadherin 21, CEECAM1 and MUC1. While loss-of-function experiments are 
still required to determine whether these membrane proteins are indeed involved in 
self-renewal and long-term growth by mediating the interaction between the bone 
marrow microenvironment and HSCs expressing STAT5, we have already 
performed studies focusing on the role in MUC1 in normal and leukemic CD34+ 
cells. These studies indeed indicate that normal CD34+ cells can be further 
subfractionated into MUC1+ cells to enrich for stem and progenitor cells, that 
overexpression of MUC1 is sufficient to elevate stem cell self-renewal of human 
CD34+ cells, and finally that MUC1 expression is increased in CD34+ cells from 
AML patients in the majority of cases64. Besides an enrichment for adhesion 
molecules in the group of genes that is upregulated by intermediate STAT5 activity 
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levels, we find that the group of downmodulated genes is also enriched for 
membrane-associated genes. Together, these data argue that STAT5 might 
strongly alter the membrane composition of stem/progenitor cells, such that 
interactions with the niche that allow long-term self-renewal are facilitated. This 
would be in line with our observations indicating that cells expressing activated 
STAT5 cannot be maintained long-term outside of a bone marrow 
microenvironment. 
Besides membrane-associated genes, we also identified a number of growth 
promoting oncogenes as STAT5 targets. These include the serine/threonine kinase 
PIM1, which was initially identified as a MYC-cofactor that predisposes to 
lymphomagenesis65. Recently, it was shown that MYC recruits PIM1 to target 
genes to phosphorylate the serine 10 residue of histone H3 on the nucleosome, 
thereby contributing to transcriptional activation66. PIM1 has previously been 
identified as a STAT5 target and can induce cytokine-independent growth of cell 
lines22. MAF was also identified as a STAT5 target. In Multiple Myeloma, the 
oncogene MAF not only stimulates cell cycle progression, but also improves the 
interaction between tumor and stromal cells67. C/EBPα  expression was reduced by 
STAT5 as we have observed previously50, and in a variety of cases low expression 
levels or impaired signalling of  C/EBPα has been associated with enhanced self-
renewal and leukemic transformation56,68-71. Importantly, the effects of STAT5 on 
these oncogenes, as well as on the cluster of genes that was enriched for 
membrane proteins, were all maximally induced or repressed at intermediate 
STAT5 activity levels and did not significantly change upon further increases in 
STAT5 activity. Yet, the phenotype did change upon a further increase in STAT5 
transactivity from a predominant growth and self-renewal phenotype at 
intermediate levels, towards a predominant differentiation phenotype upon high 
STAT5 activity. The group of target genes at high STAT5 activity levels was 
significantly enriched for secreted extracellular factors. Within this group, we 
identified the chemokine family members CCL2, -3,-5, and -22 as novel STAT5 
targets, and several potential STAT5 binding sites were found in their 5’-promoter 
sequences (unpublished observations). It has been described that several of these 
chemokines have growth inhibitory effects on murine progenitor cells as 
determined by colony assays in methylcellulose72. These genes respond in a linear 
fashion in response to STAT5 activity and reach their highest expression levels al 
maximal STAT5 activity. The same is true for the cell cycle inhibitor p21CIP, and it 
is plausible that these growth inhibitory genes might shift the balance from 
proliferation towards differentiation at the highest STAT5 transactivation levels. 
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In conclusion, we propose a model which is summarized in Fig.6. Intermediate 
STAT5 activity levels are sufficient to induce maximal levels of growth promoting 
proto-oncogenes such as PIM1 and MAF, or low levels of C/EBPα, as well as 
maximal levels of membrane-associated genes such as MUC1 that might mediate 
the enhanced interaction between human hematopoietic stem/progenitor cells with 
their bone marrow microenvironment. This pattern of gene expression will drive 
long-term expansion and self-renewal. Upon further increases in STAT5 activity, 
only specific subsets of STAT5 target genes will be further enhanced, and these 
include p21CIP and members of the chemokine family. This set of genes will 
negatively affect cell cycle progression and expansion, resulting in a shift towards a 
differentiation phenotype along the erythroid lineage. On the basis of this model we 
would predict that relatively low, but not high, levels of STAT5 transcription factor 
activity would favour leukemic transformation, and it will be challenging to perform 
these gene-dosage studies in an in vivo setting to confirm these hypotheses. Also, 
it will be intriguing to decipher why genes respond so differently to increasing levels 
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Table I. GO annotations related to gene expression changes induced by STAT5A(1*6)-ER   
Category '[STAT5]int' GO Cellular 











% of Genes in 
List in 
Category p-Value 
GO:16021: integral to membrane 3860 30.92 36 45 0.00548 
GO:31224: intrinsic to membrane 3866 30.97 36 45 0.00563 
GO:323: lytic vacuole 141 1.13 4 5 0.0127 
GO:5764: lysosome 141 1.13 4 5 0.0127 
GO:16020: membrane 4986 39.95 42 52.5 0.0152 
GO:5773: vacuole 160 1.282 4 5 0.0194 
GO:5887: integral to plasma membrane 1404 11.25 15 18.75 0.0317 
GO:31226: intrinsic to plasma membrane 1410 11.3 15 18.75 0.0328 












% of Genes in 
List in 
Category p-Value 
GO:5615: extracellular space 583 4.671 9 23.68 4.80E-05 
GO:5589: collagen type VI 2 0.016 1 2.632 0.00608 
GO:5576: extracellular region 1359 10.89 10 26.32 0.00616 
GO:5773: vacuole 160 1.282 3 7.895 0.0126 
GO:267: cell fraction 881 7.058 7 18.42 0.0157 
GO:5776: autophagic vacuole 6 0.0481 1 2.632 0.0181 
GO:5625: soluble fraction 235 1.883 3 7.895 0.0343 
GO:30934: anchoring collagen 12 0.0961 1 2.632 0.0359 
GO:5765: lysosomal membrane 13 0.104 1 2.632 0.0389 












% of Genes in 
List in 
Category p-Value 
GO:5886: plasma membrane 1970 15.78 32 28.07 0.000586 
GO:5887: integral to plasma membrane 1404 11.25 25 21.93 0.000746 
GO:31226: intrinsic to plasma membrane 1410 11.3 25 21.93 0.000795 
GO:5865: striated muscle thin filament 11 0.0881 2 1.754 0.00431 
GO:15629: actin cytoskeleton 235 1.883 7 6.14 0.00574 
GO:16021: integral to membrane 3860 30.92 48 42.11 0.00735 
GO:31224: intrinsic to membrane 3866 30.97 48 42.11 0.00758 
GO:5912: adherens junction 15 0.12 2 1.754 0.00803 
GO:31092: platelet alpha granule membrane 1 0.00801 1 0.877 0.00913 
GO:31091: platelet alpha granule 1 0.00801 1 0.877 0.00913 
GO:30054: cell junction 141 1.13 5 4.386 0.00941 
GO:16020: membrane 4986 39.95 58 50.88 0.0113 
GO:5925: focal adhesion 2 0.016 1 0.877 0.0182 
GO:5856: cytoskeleton 861 6.898 14 12.28 0.0249 
GO:42383: sarcolemma 3 0.024 1 0.877 0.0272 
GO:8074: guanylate cyclase complex, soluble 3 0.024 1 0.877 0.0272 
GO:5911: intercellular junction 132 1.058 4 3.509 0.0327 
GO:5924: cell-substrate adherens junction 4 0.032 1 0.877 0.036 
GO:5819: spindle 36 0.288 2 1.754 0.0426 
GO:5861: troponin complex 5 0.0401 1 0.877 0.0448 
GO:5862: muscle thin filament tropomyosin 5 0.0401 1 0.877 0.0448 
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Supplemental Figure 1. Validation of STAT5A(1*6)-ER Illumina gene expression data by Q-PCR 
and comparison with wt STAT5A-ER Illumina data. Q-PCR analysis were performed using primers 
and conditions listed in Supplemental Table 1. 26 out of 29 gene expression changes identified by 
Illumina were confirmed by Q-PCR. Also, STAT5A(1*6)-ER Illumina gene expression data was 
compared to wt STAT5A-ER Illumina data (500 nM 4-OHT). 
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Supplemental table 1. Primers sequences and q-PCR conditions 
 
gene forward primer reverse primer 
PIM1 cagcttcccgagtaccagtg ggcctgggatctggaatgag 
CyclinD1 gtctgcgaggaacagaagtg ggatggagttgtcggtgtag 
CyclinD2 gagctgctggctaagatgac ccagttcatcctccgacttg 
p21 actaggcggttgaatgagag aggaagtagctggcatgaag 
p27 gcaaccgacgattcttctac gtccattccatgaagtcagc 
Bcl-2 gaggctgggatgcctttgtg gggccaaactgagcagagtc 
CXCR4 aggccctagctttcttccac gtccacctcgctttcctttg 
GJA4 acctcctcagacccttacac cactggatgagagcccattg 
FLJ43339 gcctgggcaaagaagagtag tgtgggaagaggaggttgtc 
ARHGAP1 tcaccaccgagggcatcttc ctggcaggtgcagctcattg 
CXCL12 ttgacccgaagctaaagtgg cacgtctttgccctttcatc 
TUBB2B acagcagctacttcgtggag tcggagatgcgcttgaacag 
RAP1GAP tccaccaagctgccatacac atcatgtcgggcacgaaagg 
CCL22 ccgtgattacgtccgttacc cggcacagatctccttatcc 
RSG1 gttatccaggcgcagagttg ttacctggccttcccagttc 
c-MAF agaaggcgcacctggaagac ttgctgatgagcgcctcgac 
CCL3L3 ggagtgggtccagaaatacg gtcacacgcatgttcccaag 
CALB2 gcttggcggaagtacgacac tcctggagcttgggctcatc 
IGFBP5 ggctgaagcagtgaagaagg ctgaggtgcagagatgatcc 
OSM gcacagactggccgacttag tgttcctgagcccgaggatg 
SALL2 gggcactgcttaccaaccac cagctccttgccggtcaatc 
Qp27KIP cgacctgcaaccgacgattc gtcttctgaggccaggcttc 
CISH ccaggaagagccagcaagag cagcccacaggtgagacaag 
SOCS2 tgcaaggataagcggacagg cagagatgctgcagagatgg 
HBB acccagaggttctttgagtc gagcactttcttgccatgag 
HBA1 aggccctggagaggatgttc ttgccgtggcccttaacctg 
CEBPA (int) gcacgagacgtccatcgacatc ggccaggaactcgtcgttgaag 
NE gggctaatccacggaattgc cggagcgttggatgatagag 
PU1 cagatgcacgtcctcgatac tcttcttcttgctgcctgtc 
BMI1 gttccctccacctcttcttg ggctgttgctggttccattc 
GAPDH cacccactcctccacctttg ccaccaccctgttgctgtag 
HPRT agttctgtggccatctgcttag cgcccaaagggaactgatagtc 
RPL27 tccggacgcaaagctgtcatcg tcttgcccatggcagctgtcac 






Initial denaturation: 3’, 94 °C 
40 cycles of:  denaturation: 15”, 94 °C 
annealing and extension: 45”, 58 °C 
 
Fluorescent data acquisition during annealing and extension. 
 156
  157 
  
 158
